This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Stocks Insiders are Buying This Week

United Therapeutics has a market cap of $2.65 billion and an enterprise value of $2.44 billion. This stock trades at a cheap valuation, with a trailing price-to-earnings of 10.50 and a forward price-to-earnings of 9.46. Its estimated growth rate for this year is 44.5%, and for next year it's pegged at 4.3%. This is a cash-rich company, since the total cash position on its balance sheet is $503.46 million and its total debt is $273.37 million. After you back out the debt, this company has a net cash position of $230.09 million.

The CEO just bought 9,000 shares, or about $466,000 worth of stock, at $51.44 to $52.12 per share.

From a technical perspective, UTHR is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock recently bounced right off its 200-day at $50.06 a share and back above its 50-day at $51.28 a share. That bounce is quickly pushing shares of UTHR within range of triggering a near-term breakout trade.

If you're in the bull camp on UTHR, then I would look for long-biased if this stock manages to break out above some near-term overhead resistance levels at $53.48 to $54.23 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 771,969 shares. If that breakout triggers soon, then UTHR will set up to re-test or possibly take out its next major overhead resistance levels $58.38 to $59 a share. Any move above $59 will then push UTHR into new 52-week high territory, which is bullish technical price action.


Yet another name in the biotechnology and drugs complex that insiders are snapping up a huge amount of stock in is Mannkind (MKND). This company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Insiders are buying this stock into weakness, since shares are down by 20% in the last three months.

Mannkind has a market cap of $451 million and an enterprise value of $872 million. Its estimated growth rate for this year is 33.3%, and for next year it's pegged at 48.9%. This is not a cash-rich company, since the total cash position on its balance sheet is $2.12 million and its total debt is $434.82 million.

3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SNTS $0.00 0.00%
HMA $0.00 0.00%
MNKD $5.24 0.00%
SPB $89.97 0.00%
UTHR $172.96 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs